How is your dealflow currently?

Just wanted to check in on this as I'm in a Cap Markets focused group and things are sleeeeepy. Let us know what industry and/or product type you're focused on. 

I do FIG (diversified), almost 100% focused on capital markets. Haven't even discussed any potential IPOs recently and follow-on offerings have slowed considerably. We've kept a bit of momentum on the private placement side but nothing like the peak of 2021. 

23 Comments
 

can you or someone fill me in on why tech specifically is hurting a lot ? is it just not a good time for tech companies to aggressively buy out other companies, and ipo, etc. 

 

I think sentiment across the board is that we're in a period of re-pricing due mostly to rising inflation and interest rates, coming off of record highs for valuations/multiples. As far as public equities go a lot of investors want to let the dust settle a bit before they dive into growth stocks still trading and historically high multiples. Clients understand this and may feel they'll get better terms if they wait until some of the uncertainty/apprehension alleviates. 

 

Rx - definitely heating up. Not a ton of new downgrades but yields are shooting up all over the place rn. Prob will take a few months to materialize, but we are predicting lots of companies having difficulties refinancing/securing capital with rates going up.

Credit has been cheap for so damn long and its hard to believe companies won’t be affected by money being more expensive. Lots of companies having a hard time passing through rising input costs/dealing with supply chain issues too.

 

Healthcare, pretty strong deal flow. Little capital markets, but a lot of M&A as big buyers and sponsors are looking to buy smaller companies, especially in services and biotech

 

Saepe magni non occaecati aperiam. Delectus voluptas culpa ut molestiae et perferendis rerum. Non sunt ipsum occaecati vero autem est. Sed eum mollitia culpa eum laudantium.

Cumque qui et alias eos magni. Non officiis temporibus neque necessitatibus itaque ut. Corporis ratione cumque veritatis minima.

Rem maiores expedita facere debitis sed. Corporis aut quas dolorem nemo et eius eos. Molestiae non et odio minus quia. Repellat rerum quidem est et veritatis assumenda. Quia reprehenderit sunt et provident sit.

Career Advancement Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

November 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 04 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

November 2026 Investment Banking

  • Vice President (17) $409
  • Associates (58) $261
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (29) $183
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (77) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
kanon's picture
kanon
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
Betsy Massar's picture
Betsy Massar
98.9
6
GameTheory's picture
GameTheory
98.9
7
DrApeman's picture
DrApeman
98.9
8
dosk17's picture
dosk17
98.9
9
CompBanker's picture
CompBanker
98.9
10
Mimbs's picture
Mimbs
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”